EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Eloise Clarkson iD, Annabelle Lewis iD

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.70064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Eloise Clarkson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Centre for Genome Engineering and Maintenance, Brunel Univ…. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Colorectal Neoplasms, Drug Resistance, Neoplasm, Bone Morphogenetic Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bowel Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bone morphogenetic protein (BMP) antagonists have been increasingly linked to the development of colorectal cancer (CRC). BMP signalling operates in opposition to the WNT signalling pathway, which sustains stem‐cell maintenance and self‐renewal of the normal intestinal epithelium. Reduced BMP and elevated WNT signalling lead to expansion of the stem‐cell compartment and the hyperproliferation of epithelial cells, a defining characteristic of CRC. Chordin‐like‐2 (CHRDL2) is a secreted BMP antagonist, with overexpression linked to poor prognosis and variants in the gene shown to be associated with an elevated CRC risk. However, the detailed mechanism by which CHRDL2 contributes to CRC is unknown. In this study, we explored the impact of CHRDL2 overexpression on CRC cells to investigate whether CHRDL2's inhibition of BMP signalling intensifies WNT signalling and enhances the cancer stem‐cell phenotype and response to treatment. Our research approach combines 2D cancer cell lines engineered to inducibly overexpress CHRDL2 and 3D organoid models treated with extrinsic CHRDL2, complemented by RNA sequencing analysis. CHRDL2 was found to enhance the survival of organoids and CRC cells during chemotherapy and irradiation treatment due to activation of DNA damage response pathways. Organoids treated with secreted CHRDL2 exhibited elevated levels of stem‐cell markers and reduced differentiation, as evidenced by diminished villi budding. RNA‐seq analysis revealed that CHRDL2 increased the expression of stem‐cell markers, WNT signalling and other well‐established cancer‐associated pathways through BMP inhibition. These findings collectively suggest that CHRDL2 overexpression could affect response to CRC therapy by enhancing DNA repair and the stem‐cell potential of cancer cells, and its role as a biomarker should be further explored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Stem CellsColorectal NeoplasmsDrug Resistance, NeoplasmBone Morphogenetic ProteinsHumansCell Line, TumorPhenotypeOrganoidsWnt Signaling PathwayGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

WNT signalling pathwaybone‐morphogenic proteincancer stem cellchordin‐like 2colorectal cancer

Substanzen

Bone Morphogenetic Proteins

Autor:innen und Institutionen

  • Division of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Centre for Genome Engineering and Maintenance, Brunel University London, Uxbridge, UK.

ORCID-Profile: Eloise Clarkson, Annabelle Lewis

Förderung

  • Bowel Research UK

Zitieren

APA

Clarkson, E., & Lewis, A. (2025). BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.70064

Vancouver

Clarkson E, Lewis A. BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer. Molecular Oncology. 2025. doi:10.1002/1878-0261.70064

BibTeX
@article{Clarkson2025,
  author = {Clarkson, Eloise and Lewis, Annabelle},
  title = {BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.70064}
}
Kostenlos starten →